The design of BASP1 therapeutic peptides would have to include engineering of cell‐penetrating capacities, similar to the successful application of cell‐penetrating peptides based on the dominant‐negative MYC inhibitor Omomyc in various MYC‐related cancer models including triple‐negative breast cancer cells (Beaulieu et al., 2019; Wang et al., 2019). This evidence concerns the gene BASP1 and cancer.